ATE338544T1 - Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren - Google Patents

Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren

Info

Publication number: ATE338544T1
Authority: AT; Austria
Prior art keywords: inhibitors; cox; optionally; nitric oxide; cyclooxygenase
Prior art date: 2000-12-21

Application number

AT01998052T

Other languages

English (en)

Inventor

Subhash P Khanapure

David S Garvey

Richard A Earl

Maiko Ezawa

Xinqin Fang

Ricky D Gaston

Original Assignee

Nitromed Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-21

Filing date

2001-12-21

Publication date

2006-09-15

2001-12-21 Application filed by Nitromed Inc filed Critical Nitromed Inc

2006-09-15 Application granted granted Critical

2006-09-15 Publication of ATE338544T1 publication Critical patent/ATE338544T1/de

Links

102000010907 Cyclooxygenase 2 Human genes 0.000 title abstract 7
108010037462 Cyclooxygenase 2 Proteins 0.000 title abstract 7
229940124639 Selective inhibitor Drugs 0.000 title abstract 4
150000001875 compounds Chemical class 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 5
239000003112 inhibitor Substances 0.000 abstract 5
229940111134 coxibs Drugs 0.000 abstract 3
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 abstract 2
102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 abstract 2
108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 abstract 2
UFPQIRYSPUYQHK-VRKJBCFNSA-N Leukotriene A4 Natural products CCCCCC=C/CC=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(=O)O UFPQIRYSPUYQHK-VRKJBCFNSA-N 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
UFPQIRYSPUYQHK-WAQVJNLQSA-N leukotriene A4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(O)=O UFPQIRYSPUYQHK-WAQVJNLQSA-N 0.000 abstract 2
229940124597 therapeutic agent Drugs 0.000 abstract 2
-1 H2 antagonists Substances 0.000 abstract 1
241000590002 Helicobacter pylori Species 0.000 abstract 1
229940122957 Histamine H2 receptor antagonist Drugs 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 1
108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 1
102000011779 Nitric Oxide Synthase Type II Human genes 0.000 abstract 1
108010076864 Nitric Oxide Synthase Type II Proteins 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
206010037660 Pyrexia Diseases 0.000 abstract 1
229940122388 Thrombin inhibitor Drugs 0.000 abstract 1
229940035676 analgesics Drugs 0.000 abstract 1
239000000730 antalgic agent Substances 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
229940034982 antineoplastic agent Drugs 0.000 abstract 1
229940127218 antiplatelet drug Drugs 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
239000000850 decongestant Substances 0.000 abstract 1
229940124581 decongestants Drugs 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
239000002934 diuretic Substances 0.000 abstract 1
229940030606 diuretics Drugs 0.000 abstract 1
230000002526 effect on cardiovascular system Effects 0.000 abstract 1
239000000066 endothelium dependent relaxing factor Substances 0.000 abstract 1
230000002496 gastric effect Effects 0.000 abstract 1
229940037467 helicobacter pylori Drugs 0.000 abstract 1
239000000938 histamine H1 antagonist Substances 0.000 abstract 1
239000004093 hydrolase inhibitor Substances 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
150000002535 isoprostanes Chemical class 0.000 abstract 1
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 abstract 1
231100000417 nephrotoxicity Toxicity 0.000 abstract 1
239000002840 nitric oxide donor Substances 0.000 abstract 1
239000000236 nitric oxide synthase inhibitor Substances 0.000 abstract 1
229940005483 opioid analgesics Drugs 0.000 abstract 1
239000000106 platelet aggregation inhibitor Substances 0.000 abstract 1
239000000612 proton pump inhibitor Substances 0.000 abstract 1
229940126409 proton pump inhibitor Drugs 0.000 abstract 1
229940044551 receptor antagonist Drugs 0.000 abstract 1
239000002464 receptor antagonist Substances 0.000 abstract 1
CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 abstract 1
230000001624 sedative effect Effects 0.000 abstract 1
239000000952 serotonin receptor agonist Substances 0.000 abstract 1
150000003431 steroids Chemical class 0.000 abstract 1
125000003107 substituted aryl group Chemical group 0.000 abstract 1
239000000758 substrate Substances 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
239000003868 thrombin inhibitor Substances 0.000 abstract 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
230000029663 wound healing Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/56—Radicals substituted by sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Pregnancy & Childbirth (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Toxicology (AREA)
Nutrition Science (AREA)

AT01998052T 2000-12-21 2001-12-21 Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren ATE338544T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US25693200P	2000-12-21	2000-12-21

Publications (1)

Publication Number	Publication Date
ATE338544T1 true ATE338544T1 (de)	2006-09-15

Family

ID=22974190

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01998052T ATE338544T1 (de)	2000-12-21	2001-12-21	Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren

Country Status (8)

Country	Link
US (3)	US6706724B2 (de)
EP (1)	EP1406609B1 (de)
JP (1)	JP4092203B2 (de)
AT (1)	ATE338544T1 (de)
AU (1)	AU2002249812B2 (de)
CA (1)	CA2432642A1 (de)
DE (1)	DE60122939T2 (de)
WO (1)	WO2002060378A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5824669A (en) *	1996-03-22	1998-10-20	Nitromed, Inc.	Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
EP1414432A4 (de) *	2001-08-10	2008-01-09	Nitromed Inc	Anwendungsverfahren für neue schwefelhaltige organische nitratverbindungen
AU2003223491A1 (en) *	2002-04-05	2003-10-27	Nitromed, Inc.	Nitric oxide donors, compositions and methods of use
US20040038947A1 (en) *	2002-06-14	2004-02-26	The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services	Method of treating ischemia/reperfusion injury with nitroxyl donors
EP1527045A1 (de) *	2002-07-26	2005-05-04	Merck Frosst Canada & Co.	Stickstoffmonoxid freisetzende prodrugs von diaryl-2-(5h)-furanonen als cyclooxygenase-2-inhibitoren
US6936639B2 (en)	2002-08-21	2005-08-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Nitroxyl progenitors in the treatment of heart failure
US7507531B2 (en)	2002-10-17	2009-03-24	Decode Genetics Chf.	Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
WO2005027886A2 (en) *	2003-09-17	2005-03-31	Decode Genetics Ehf.	Methods of preventing or treating recurrence of myocardial infarction
CA2502357A1 (en) *	2002-10-17	2004-04-29	Decode Genetics Ehf.	Susceptibility gene for myocardial infarction; methods of treatment
US7851486B2 (en)	2002-10-17	2010-12-14	Decode Genetics Ehf.	Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
FR2845917B1 (fr) *	2002-10-21	2006-07-07	Negma Gild	Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
EP1594470A4 (de) *	2003-02-19	2007-10-17	Biovail Lab Int Srl	Schnell absorbierende selektive 5-ht-agonisten-formulierungen
CA2517490A1 (en) *	2003-03-05	2004-12-02	Merck Frosst Company	Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
US20050009789A1 (en) *	2003-05-13	2005-01-13	The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Service	Cyclooxygenase inhibition with nitroxyl
US20050113409A1 (en) *	2003-09-03	2005-05-26	Pharmacia Corporation	Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
WO2005076987A2 (en) *	2004-02-10	2005-08-25	Santarus, Inc.	Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US7235688B1 (en)	2004-11-04	2007-06-26	University Of Notre Dame Du Lac	Process for preparing histone deacetylase inhibitors and intermediates thereof
US20070021612A1 (en) *	2004-11-04	2007-01-25	University Of Notre Dame Du Lac	Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
US20060276440A1 (en) *	2005-01-03	2006-12-07	An Wenqian F	Treatment of inflammatory disorders
US20090298795A1 (en) *	2005-06-23	2009-12-03	The Johns Hopins University	Thiol-Sensitive Positive Inotropes
US7801502B2 (en) *	2006-12-18	2010-09-21	Aai Corporation	Method for implementing continuous radio frequency (RF) alignment in advanced electronic warfare (EW) signal stimulation systems
CN101668425A (zh) *	2007-03-02	2010-03-10	田纳西州立大学研究基金会	三芳基/杂芳族大麻素类和其应用
EP2014284A1 (de) *	2007-06-15	2009-01-14	Novartis AG	Pharmazeutische Zusammensetzungen und deren Verwendungen
US8455520B2 (en) *	2007-07-17	2013-06-04	Merck Sharp & Dohme Corp.	Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
US20110160200A1 (en) *	2009-11-23	2011-06-30	Cardioxyl Pharmaceuticals, Inc.	Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
CN105130855B (zh) *	2009-12-07	2018-05-25	约翰斯霍普金斯大学	二酰基化的羟基胺衍生物及其用途
AU2010328234B2 (en) *	2009-12-07	2016-05-12	Cardioxyl Pharmaceuticals, Inc.	N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives
US8409628B2 (en)	2010-02-04	2013-04-02	Penguin IP Holdings, Inc.	Methods and compositions for oxygenation of skin to treat skin disorders
WO2011123619A2 (en)	2010-03-31	2011-10-06	Penguin Ip Holdings Inc.	Permeable mixtures, methods and compositions for the skin

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9113628D0 (en)	1991-06-25	1991-08-14	Ici Plc	Heterocyclic derivatives
GB9113626D0 (en)	1991-06-25	1991-08-14	Ici Plc	Heterocyclic compounds
IT1256345B (it)	1992-08-20	1995-12-01		Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
JP2802706B2 (ja)	1992-09-28	1998-09-24	富士写真フイルム株式会社	複素環化合物の製造方法
EP0596395B1 (de)	1992-11-04	2000-06-28	Clariant GmbH	Verfahren zur Herstellung fluorierter Benzile
IT1256450B (it)	1992-11-26	1995-12-05	Soldato Piero Del	Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
US5474995A (en)	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
DK77393D0 (da)	1993-06-29	1993-06-29	Novo Nordisk As	Aktivering af enzymer
EP0722434B1 (de)	1993-10-06	1998-07-29	Nicox S.A.	Salzetersaüreester mit entzündungshemmender und/oder schmerzlindernder wirkung und verfahren zu deren herstellung
WO1995030641A1 (en)	1994-05-10	1995-11-16	Nicox S.A.	Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities
US5593994A (en)	1994-09-29	1997-01-14	The Dupont Merck Pharmaceutical Company	Prostaglandin synthase inhibitors
US5739166A (en) *	1994-11-29	1998-04-14	G.D. Searle & Co.	Substituted terphenyl compounds for the treatment of inflammation
JP3802581B2 (ja) *	1995-03-01	2006-07-26	富山化学工業株式会社	新規なビフェニル誘導体またはその塩およびそれらを含有する抗炎症剤
US6051588A (en) *	1995-04-19	2000-04-18	Nitromed Inc	Nitroso esters of β-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US5703073A (en) *	1995-04-19	1997-12-30	Nitromed, Inc.	Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US6043232A (en) *	1997-07-23	2000-03-28	Nitromed, Inc.	Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US5567711A (en)	1995-04-19	1996-10-22	Abbott Laboratories	Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
US5710159A (en)	1996-05-09	1998-01-20	The Dupont Merck Pharmaceutical Company	Integrin receptor antagonists
US5700816A (en)	1995-06-12	1997-12-23	Isakson; Peter C.	Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
IL135495A (en)	1995-09-28	2002-12-01	Hoechst Ag	Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
IT1276071B1 (it)	1995-10-31	1997-10-24	Nicox Ltd	Compositi ad attivita' anti-infiammatoria
IT1282686B1 (it)	1996-02-26	1998-03-31	Nicox Sa	Composti in grado di ridurre la tossicita' da farmaci
ATE233743T1 (de)	1996-04-12	2003-03-15	Searle & Co	N-((4-(5-methyl-3-phenylisoxazol-4- yl)phenyl)sulphonylpropylamid und sein natriumsalz als pro-pharmakon von cox-2 inhibitoren
IT1288123B1 (it)	1996-09-04	1998-09-10	Nicox Sa	Uso di nitroderivati per l'incontinenza urinaria
DE19651099A1 (de)	1996-12-09	1998-06-10	Consortium Elektrochem Ind	Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
AU731305B2 (en)	1997-05-23	2001-03-29	Dow Agrosciences Llc	1-alkyl-4-benzoyl-5-hydroxypyrazole compounds and their use as herbicides
AU8020398A (en)	1997-06-10	1998-12-30	Unilever Plc	Method for enhancing the activity of an enzyme, bleach composition, detergent composition and process for inhibiting dye transfer
UA57081C2 (uk)	1997-06-16	2003-06-16	Пфайзер Продактс Інк.	Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування
US6046217A (en) *	1997-09-12	2000-04-04	Merck Frosst Canada & Co.	2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
EP1015431B1 (de)	1997-09-12	2005-04-20	Merck Frosst Canada & Co.	2-aminopyridine als inhibitoren von cyclooxygenase-2
CA2301742C (en)	1997-09-12	2004-05-18	Richard Friesen	2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
DE19741400A1 (de) *	1997-09-19	1999-03-25	Bayer Ag	Benzyl-biphenyle
GB9721437D0 (en)	1997-10-10	1997-12-10	Glaxo Group Ltd	Heteroaromatic compounds and their use in medicine
CA2306646A1 (en)	1997-10-22	1999-04-29	Merck & Co., Inc.	Combination therapy for reducing the risks associated with cardio- and cerebrovascular disease
US6245797B1 (en) *	1997-10-22	2001-06-12	Merck & Co., Inc.	Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
CA2314978C (en)	1997-12-23	2008-05-06	Novo Nordisk A/S	Process for removal of excess dye from printed or dyed fabric or yarn
ID24959A (id)	1998-01-28	2000-08-31	Shionogi & Co	Senyawa-senyawa trisiklik yang baru
IT1299198B1 (it)	1998-03-05	2000-02-29	Nicox Sa	Sali nitrati di farmaci antiulcera
IT1298338B1 (it)	1998-03-05	1999-12-20	Nicox Sa	Composizioni farmaceutiche per l'ulcera
WO1999045913A1 (en)	1998-03-13	1999-09-16	Merck & Co., Inc.	Combination therapy and composition for acute coronary ischemic syndrome and related conditions
CN1299405A (zh)	1998-05-08	2001-06-13	汉高两合股份公司	漂白消毒制剂
SE9802333D0 (sv) *	1998-06-29	1998-06-29	Astra Pharma Prod	Novel combination
EP1098892A1 (de)	1998-07-20	2001-05-16	MERCK PATENT GmbH	Biphenyl derivate
IT1303672B1 (it)	1998-07-28	2001-02-23	Nicox Sa	Sali nitrati di farmaci attivi nei disordini ossei
WO2000018352A2 (en)	1998-09-28	2000-04-06	Merck & Co., Inc.	A method for treating inflammatory diseases by administering a thrombin inhibitor
US6297260B1 (en) *	1998-10-30	2001-10-02	Nitromed, Inc.	Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
IT1307928B1 (it)	1999-01-26	2001-11-29	Nicox Sa	Metodo di sintesi di nitrossimetilfenil esteri di derivatidell'aspirina.
IT1308633B1 (it)	1999-03-02	2002-01-09	Nicox Sa	Nitrossiderivati.
IT1311922B1 (it)	1999-04-13	2002-03-20	Nicox Sa	Composti farmaceutici.
IT1311921B1 (it)	1999-04-13	2002-03-20	Nicox Sa	Composti farmaceutici.
IT1311924B1 (it)	1999-04-13	2002-03-20	Nicox Sa	Composti farmaceutici.
IT1311923B1 (it)	1999-04-13	2002-03-20	Nicox Sa	Composti farmaceutici.
JO2308B1 (en)	1999-05-31	2005-09-12	اف. هوفمان- لاروش أيه جي‏	Derivatives of phenylpyrmidine
TWI243672B (en)	1999-06-01	2005-11-21	Astrazeneca Ab	New use of compounds as antibacterial agents
IT1312115B1 (it)	1999-06-24	2002-04-04	Nicox Sa	Composti amorfi e relative composizioni farmaceutiche
ITMI991517A1 (it)	1999-07-09	2001-01-09	Nicox Sa	Procedimento per ottenere nitrossimetil fenil esterni di derivati dell'acido salicilico
IT1313596B1 (it)	1999-08-04	2002-09-09	Nicox Sa	Processo per la preparazione di nitrossialchil esteri del naproxene
IT1314184B1 (it)	1999-08-12	2002-12-06	Nicox Sa	Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
AP2002002582A0 (en) *	1999-12-23	2002-09-30	Nitromed Inc	Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
IT1317735B1 (it)	2000-01-26	2003-07-15	Nicox Sa	Sali di agenti antimicrobici.
AU3653301A (en)	2000-01-28	2001-08-07	Merck & Co., Inc.	Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
GB0002336D0 (en)	2000-02-01	2000-03-22	Glaxo Group Ltd	Medicaments
KR100774014B1 (ko)	2000-05-19	2007-11-08	오츠카 세이야쿠 가부시키가이샤	헬리코박터 파이로리 감염의 진단용 제제
SE0002476D0 (sv)	2000-06-30	2000-06-30	Astrazeneca Ab	New compounds

2001
- 2001-12-21 DE DE60122939T patent/DE60122939T2/de not_active Expired - Fee Related
- 2001-12-21 WO PCT/US2001/048823 patent/WO2002060378A2/en not_active Ceased
- 2001-12-21 EP EP01998052A patent/EP1406609B1/de not_active Expired - Lifetime
- 2001-12-21 US US10/024,046 patent/US6706724B2/en not_active Expired - Fee Related
- 2001-12-21 AU AU2002249812A patent/AU2002249812B2/en not_active Ceased
- 2001-12-21 AT AT01998052T patent/ATE338544T1/de not_active IP Right Cessation
- 2001-12-21 CA CA002432642A patent/CA2432642A1/en not_active Abandoned
- 2001-12-21 JP JP2002560574A patent/JP4092203B2/ja not_active Expired - Fee Related
2003
- 2003-12-10 US US10/730,979 patent/US6825185B2/en not_active Expired - Fee Related
2004
- 2004-10-21 US US10/969,079 patent/US20050059665A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20040116431A1 (en)	2004-06-17
WO2002060378A2 (en)	2002-08-08
JP4092203B2 (ja)	2008-05-28
EP1406609A4 (de)	2004-04-14
US20050059665A1 (en)	2005-03-17
US20020119977A1 (en)	2002-08-29
JP2005502587A (ja)	2005-01-27
US6706724B2 (en)	2004-03-16
AU2002249812B2 (en)	2005-11-10
CA2432642A1 (en)	2002-08-08
EP1406609B1 (de)	2006-09-06
US6825185B2 (en)	2004-11-30
DE60122939T2 (de)	2007-01-11
WO2002060378A3 (en)	2003-12-31
DE60122939D1 (de)	2006-10-19
EP1406609A2 (de)	2004-04-14

Legal Events

Date	Code	Title	Description
2007-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE338544T1 (de)	2006-09-15	Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
AP2002002582A0 (en)	2002-09-30	Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
NO20003520D0 (no)	2000-07-07	Lagringsdyktige sammensetninger og slurryer og anvendelse av samme for sementering av olje- og gassbrønner
WO2004002409A3 (en)	2004-08-19	Cyclooxygenase-2 selective inhibitors, compositions and methods of use
HUP0400601A3 (en)	2004-08-30	Use of moo3 as corrosion inhibitor, and coating composition containing such an inhibitor
NO20021587D0 (no)	2002-04-04	Sementeringsblandinger og bruk av slike blandinger for sementering av brönner eller lignende
NO20030213D0 (no)	2003-01-16	Anvendelse av D2/D3 reseptor-agonister for behandling av fibromyalgi
WO2002032874A8 (en)	2003-11-13	Substituted heterocyclic compounds for treating multidrug resistance
IL153608A0 (en)	2003-07-06	Composition for the chemical mechanical polishing of metal and metal/dielectric structures
EP1513881A4 (de)	2005-07-13	Formulierungen für auf korrosion ansprechende beschichtungen zum schutz von metalloberflächen
AU2002340010A1 (en)	2003-04-07	Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
NO20000630L (no)	2000-08-10	FremgangsmÕter og sammensetninger for sementering av rørstrenger i borehull
DK12497A (da)	1997-08-13	Korrisionsinhiberende overtrækssammensætninger til metaller
NO20033580L (no)	2003-10-02	Fremgangsmåte og komposisjon til å hindre dannelse av hydrokarbonhydrater
WO2004012659A3 (en)	2004-10-07	Nitrosated proton pump inhibitors, compositions and methods of use
NO20000475L (no)	2000-09-18	Korrosjonsinhibitorsammensetninger, fremgangsmÕte for anvendelse samt fremgangsmÕte for fremstilling av disse
NO20081721L (no)	2008-04-08	Stabil fast formulering av sertindol
NO20035124D0 (no)	2003-11-17	Fremgangsmåte for å hindre ekstern korrosjon på en isolert rörledning
DK1673310T3 (da)	2009-05-18	Formulering til korrosion og skal-inhibering
DE60235213D1 (de)	2010-03-11	Zusammensetzung für Fluorharz-Pulverlack
WO2005112903A3 (en)	2006-02-02	Use of ghrelin antagonists for improving cognition and memory
NO20020643D0 (no)	2002-02-08	Fremgangsmåte og anordning for evaluering av kapasiteten borefluider til å danne hydrater under oljeboring
IS7334A (is)	2004-06-23	Bensóþíasól- og bensoxasól-4,7-díonafleiður og notkun þeirra sem cdc25 fosfatasatálma
IS6880A (is)	2003-07-21	Notkun á mótlyfjum viðtaka GAL3 til þess að meðhöndla depru og/eða kvíða og efnasambönd sem eru nytsöm við aðferðirnar
BR0114677A (pt)	2003-10-07	Inibição da dependência de fator de crescimento de células de tumores